Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist.
申请人:OntoChem GmbH
公开号:EP2243494A1
公开(公告)日:2010-10-27
A treatment using a hydroxysteroid dehydrogenase reductase inhibitor combined with a mineralocorticoid receptor antagonist is provided which overcomes the problem that manipulating cortisol levels by a single compound therapy induces other pathologies or side effects, while the original condition that required treatment is ameliorated.
Nouveaux dérivés stéroides 7-alkylés, leur procédé de préparation, leur application comme médicament et les compositions pharmaceutiques les renfermant
申请人:ROUSSEL-UCLAF
公开号:EP0018245B1
公开(公告)日:1982-06-02
UTILISATION DES COMPOSES ANTIMINERALOCORTICOIDES CONTRE LE SYNDROME DE SEVRAGE DES NARCOTIQUES
申请人:Aventis Pharma S.A.
公开号:EP0863760B1
公开(公告)日:2001-12-05
New use of antimineralocorticoid compounds against narcotic withdrawal syndrome
申请人:Aventis Pharma S.A.
公开号:US20040242552A1
公开(公告)日:2004-12-02
A method of treating narcotic withdrawal symptoms in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of a compound having anti-mineralocorticoid activity sufficient to treat narcotic withdrawal sypmtoms.